The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbrdn Asiafocus Regulatory News (AAS)

Share Price Information for Abrdn Asiafocus (AAS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 273.00
Bid: 272.00
Ask: 276.00
Change: 2.00 (0.74%)
Spread: 4.00 (1.471%)
Open: 272.00
High: 276.00
Low: 272.00
Prev. Close: 271.00
AAS Live PriceLast checked at -
abrdn Asia Focus is an Investment Trust

To maximise long-term total return from a portfolio made up predominantly of smaller quoted companies (with a market cap of up to approximately USD 1.5bn at the time of investment) in the economies of Asia and Australasia, ex Japan.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CULS Conversion Notice

21 Oct 2021 15:11

RNS Number : 8567P
Aberdeen Standard Asia Focus PLC
21 October 2021
 

Aberdeen Standard Asia Focus PLC (the "Company")

Legal Entity Identifier (LEI): 5493000FBZP1J92OQY70

 

2.25 per cent. Convertible Unsecured Loan Stock 2025

21 October 2021

 

Reminder to CULS Holders of Conversion Rights

The Company reminds holders ("CULS Holders") of 2.25 per cent. convertible unsecured loan stock 2025 ("CULS") constituted by the Trust Deed dated 24 May 2018 that they have the right to convert ("Conversion Right") the whole or such part (being an integral multiple of £1 nominal) of their CULS as they may specify into fully paid Ordinary shares of 25p each in the capital of the Company ("Ordinary Shares") at any time during the period of 28 days ending on 30 November 2021 (the "Conversion Date") in accordance with the terms of issue of the CULS which were set out in the prospectus of the Company dated 20 April 2018.

This announcement is issued by way of a reminder only and is not to be read as a recommendation to CULS Holders to exercise their Conversion Rights. You are not obliged to exercise your right to convert and if you do not convert on this occasion you will have further opportunities to do so in May and November each year up to 31 May 2025. Notices will be issued via RNS reminding CULS Holders who do not exercise their Conversion Rights in full on this occasion of their rights to convert at subsequent opportunities.

Basis of Conversion

The number of Ordinary Shares to be issued by the Company on the exercise of a Conversion Right shall be determined by dividing the nominal amount of the CULS to be converted by the conversion price of 1,465 pence. Fractions of Ordinary Shares will not be issued on exercise of Conversion Rights, and no payment of cash or other adjustment will be made in lieu thereof.

Considerations for CULS Holders

Whether or not CULS Holders decide to convert their CULS will depend, among other things, on their own individual circumstances including their tax positions. The following factor may be of relevance for CULS Holders considering whether to convert their CULS:

 

Market value: The market value of the Ordinary Shares into which the CULS would convert is currently below the market value of the CULS. By way of example, £100 nominal of CULS had a mid-market value of £104.75 as at 20 October 2021. £100 nominal of CULS would convert into 6 Ordinary Shares, which would have had a mid-market value of approximately £85.35 on the same date. This represents £19.40 less than the mid-market value of the CULS.

 

Note: The above analysis is based on the information set out in the Schedule and does not take into account any tax which might be payable on CULS Holders' capital returns.

 

CULS held in certificated form

Holders of CULS in certificated form should refer to the instructions on their CULS certificate(s). In order to exercise the Conversion Rights which are conferred by any CULS held in certificated form, the CULS Holder must lodge the relevant CULS certificate(s) at the office of the Company's Registrars, Equiniti Limited, Corporate Actions, Aspect House, Spencer Road, Lancing, West Susex BN99 6DA during the period of 28 days ending on 30 November 2021 at 5.00pm, having completed and signed the notice of exercise of Conversion Rights thereon. Once lodged, a notice of exercise of Conversion Rights shall be irrevocable, save with the consent of the Company.

CULS held in uncertificated form

CREST members should refer to the CREST Manual for information on the CREST procedures and authentication required to effect conversion. The Conversion Rights which are conferred by any CULS held in uncertificated form shall be exercisable if an uncertificated conversion notice is received during the period of 28 days ending on 30 November 2021. The prescribed form of uncertificated conversion notice is a Transfer To Equity ("TTE") instruction which, on settlement will have the effect of crediting a stock account of the Registrar in accordance with the details specified below. The TTE instruction must be properly authenticated in accordance with Euroclear's specifications and must contain the following details in addition to any other information required:

(a) the nominal amount of CULS in respect of which Conversion Rights are being exercised;

(b) the participant ID of the CULS Holder;

(c) the member account ID of the CULS Holder;

(d) the Registrar's participant ID: this is: 6RA18;

(e) the Registrar's member account ID: this is: RA504902;

(f) the corporate action number, which will be allocated by Euroclear and can be found by viewing the relevant corporate action details in CREST;

(g) the corporate action ISIN: this is: GB00BFZ0WT29; and

(h) the intended settlement date: this will be 30 November 2021.

The TTE instruction should be input to settle by no later than 1.00pm on 30 November 2021 in order to receive Ordinary Shares arising from conversion within 14 days thereafter. Once lodged, an uncertificated conversion notice shall be irrevocable, save with the consent of the Company.

Issue of Ordinary shares

Ordinary Shares arising on conversion will be sent in certificated form where CULS is held in certificated form, and uncertificated form where CULS is held in uncertificated form.

Ordinary Shares allotted pursuant to the exercise of Conversion Rights will be allotted not later than 14 days after, and with effect from, the Conversion Date.

Certificates for Ordinary Shares, and certificates for the balance of any CULS not converted, will be despatched to holder(s) in accordance with their instructions not later than 28 days after the Conversion Date.

The Registrar will instruct Euroclear to credit the Participant ID and Member ID Account as specified in validly received uncertificated conversion notices with the number of Ordinary Shares arising on conversion, and the balance of any CULS not converted, by no later than the date upon which dealings in the Ordinary Shares are due to commence, which will be within 14 days from the Conversion Date.

Interest on CULS converted will be payable up to (but excluding) 30 November 2021 and will cease to accrue thereafter.

Enquiries

If you have any queries regarding the above procedures, these should be referred to the Company's Registrar, Equiniti Limited, on telephone number: 0371 384 2050 (from within the UK). This helpline is available between 8.30am and 5.30pm (UK time) Monday to Friday (except public holidays in England and Wales) or +44 (0)371 384 2050 (from outside the UK). Calls from outside the UK will be charged at international rates. Please note that calls may be monitored or recorded.

 

For and on behalf of Aberdeen Standard Asia Focus PLC

21 October 2021

 

 

 

 

Schedule 1:

Market Prices of CULS and Ordinary Shares (derived from Bloomberg) and NAV of the Ordinary Shares:

 

2021

 

Ordinary

Share Price (p)

2.25% CULS Price (p)

NAV

(diluted including income) (p)

30 April 2021

1285

100.95

1449.99

28 May 2021

1270

101.50

1432.06

30 June 2021

1310

102.75

1517.01

30 July 2021

1330

103.50

1532.23

31 August 2021

1385

103.45

1566.77

30 September 2021

1440

104.05

1587.25

20 October 2021

1422.5

104.75

1599.50

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDKDBKQBDDAKB
Date   Source Headline
30th Apr 202411:20 amRNSGearing disclosure
29th Apr 202412:38 pmRNSNet Asset Value(s)
26th Apr 20245:23 pmRNSTransaction in Own Shares
26th Apr 202412:45 pmRNSNet Asset Value(s)
25th Apr 20241:27 pmRNSNet Asset Value(s)
24th Apr 20245:41 pmRNSTransaction in Own Shares
24th Apr 20245:07 pmRNSCULS Interest Payment Date
24th Apr 20245:06 pmRNSCULS Conversion Notice
24th Apr 202412:11 pmRNSNet Asset Value(s)
23rd Apr 20245:15 pmRNSTransaction in Own Shares
23rd Apr 202412:47 pmRNSNet Asset Value(s)
22nd Apr 20242:04 pmRNSGearing disclosure
22nd Apr 202412:21 pmRNSNet Asset Value(s)
19th Apr 202412:46 pmRNSNet Asset Value(s)
18th Apr 20245:08 pmRNSTransaction in Own Shares
18th Apr 20243:44 pmRNSHolding(s) in Company
18th Apr 202412:36 pmRNSNet Asset Value(s)
17th Apr 20245:20 pmRNSTransaction in Own Shares
17th Apr 202412:08 pmRNSNet Asset Value(s)
16th Apr 20241:00 pmRNSNet Asset Value(s)
15th Apr 20245:43 pmRNSPortfolio Disclosures
15th Apr 20243:27 pmRNSGearing Disclosures
15th Apr 202412:48 pmRNSNet Asset Value(s)
12th Apr 202412:56 pmRNSNet Asset Value(s)
12th Apr 202412:38 pmRNSDoc re. Half Yearly Report
11th Apr 202412:42 pmRNSNet Asset Value(s)
10th Apr 20245:21 pmRNSTransaction in Own Shares
10th Apr 202412:53 pmRNSNet Asset Value(s)
9th Apr 202411:59 amRNSNet Asset Value(s)
8th Apr 20245:17 pmRNSTransaction in Own Shares
8th Apr 20242:46 pmRNSGearing disclosure
8th Apr 20241:00 pmRNSNet Asset Value(s)
5th Apr 202412:33 pmRNSNet Asset Value(s)
4th Apr 202412:47 pmRNSNet Asset Value(s)
3rd Apr 20244:38 pmRNSHolding(s) in Company
3rd Apr 202412:47 pmRNSNet Asset Value(s)
2nd Apr 20243:33 pmRNSGearing disclosure
2nd Apr 202410:56 amRNSHolding(s) in Company
2nd Apr 202410:17 amRNSTotal Voting Rights
28th Mar 20242:04 pmRNSNet Asset Value(s)
28th Mar 20247:00 amRNSHalf-year Report
27th Mar 20244:04 pmRNSHolding(s) in Company
27th Mar 202412:19 pmRNSNet Asset Value(s)
26th Mar 202412:24 pmRNSNet Asset Value(s)
25th Mar 20243:58 pmRNSGearing disclosure
25th Mar 202412:06 pmRNSNet Asset Value(s)
22nd Mar 20245:13 pmRNSTransaction in Own Shares
22nd Mar 202412:16 pmRNSNet Asset Value(s)
21st Mar 20241:17 pmRNSNet Asset Value(s)
20th Mar 20244:59 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.